The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial ...

New research could pave the way toward a new method of pulmonary arterial hypertension diagnosis and monitoring.

In the 1980s, when Stella Kourembanas, MD, began her career in neonatology, she cared for newborns with pulmonary ...

As the U.S. stock market faces a sell-off driven by concerns over tariffs and economic uncertainty, investors are increasingly looking for opportunities that can offer resilience and potential growth.

Safety of a Potential New Treatment to Manage Complications from Sickle Cell Disease Apr. 11, 2024 — A drug approved to treat pulmonary arterial hypertension may be effective at managing ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...